S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
'Civil War’ continues box-office campaign at No. 1
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
Intuitive Surgical Leads the Robotic Surgery Movement
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
'Civil War’ continues box-office campaign at No. 1
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
Intuitive Surgical Leads the Robotic Surgery Movement
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
'Civil War’ continues box-office campaign at No. 1
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
Intuitive Surgical Leads the Robotic Surgery Movement
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
'Civil War’ continues box-office campaign at No. 1
Lithium Overdose: Can These 2 Lithium Stocks Recover in 2024?
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
Intuitive Surgical Leads the Robotic Surgery Movement
NASDAQ:INAB

IN8bio (INAB) Stock Price, News & Analysis

$1.03
-0.02 (-1.90%)
(As of 04/19/2024 08:50 PM ET)
Today's Range
$0.99
$1.09
50-Day Range
$0.95
$1.30
52-Week Range
$0.65
$3.95
Volume
282,500 shs
Average Volume
318,771 shs
Market Capitalization
$32.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.75

IN8bio MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
943.7% Upside
$10.75 Price Target
Short Interest
Healthy
0.18% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.70) to ($0.42) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.05 out of 5 stars

Medical Sector

334th out of 908 stocks

Biological Products, Except Diagnostic Industry

46th out of 153 stocks

INAB stock logo

About IN8bio Stock (NASDAQ:INAB)

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

INAB Stock Price History

INAB Stock News Headlines

Now Open: Crypto emergency update
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
Now Open: Crypto emergency update
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
INAB Stock Earnings: IN8bio Misses EPS for Q4 2023
IN8bio to Present at Upcoming Investor Conferences
IN8bio Appoints Dr. Corinne Epperly to Board of Directors
See More Headlines
Receive INAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IN8bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/14/2024
Today
4/21/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:INAB
Fax
N/A
Employees
31
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.75
High Stock Price Target
$14.00
Low Stock Price Target
$7.50
Potential Upside/Downside
+943.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-30,010,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.78 per share

Miscellaneous

Free Float
21,434,000
Market Cap
$32.95 million
Optionable
Not Optionable
Beta
-0.01
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Tai-Wei Ho (Age 47)
    Co-Founder, President, CEO & Director
    Comp: $837k
  • Dr. Kate Rochlin Ph.D. (Age 43)
    Chief Operating Officer
    Comp: $565.4k
  • Dr. Trishna Goswami M.D. (Age 46)
    Chief Medical Officer
    Comp: $638.51k
  • Dr. Lawrence S. Lamb Ph.D. (Age 70)
    Executive VP, Co-Founder & Chief Scientific Officer
    Comp: $482.47k
  • Mr. Patrick McCall CPA (Age 41)
    CFO & Secretary
    Comp: $519.35k
  • Mr. Michael McNamara
    Vice President of Accounting

INAB Stock Analysis - Frequently Asked Questions

Should I buy or sell IN8bio stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IN8bio in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" INAB shares.
View INAB analyst ratings
or view top-rated stocks.

What is IN8bio's stock price target for 2024?

2 brokerages have issued 1 year price targets for IN8bio's shares. Their INAB share price targets range from $7.50 to $14.00. On average, they anticipate the company's stock price to reach $10.75 in the next year. This suggests a possible upside of 943.7% from the stock's current price.
View analysts price targets for INAB
or view top-rated stocks among Wall Street analysts.

How have INAB shares performed in 2024?

IN8bio's stock was trading at $1.38 at the beginning of 2024. Since then, INAB shares have decreased by 25.4% and is now trading at $1.03.
View the best growth stocks for 2024 here
.

Are investors shorting IN8bio?

IN8bio saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 51,600 shares, a decrease of 39.2% from the March 15th total of 84,800 shares. Based on an average daily trading volume, of 168,200 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.2% of the shares of the company are short sold.
View IN8bio's Short Interest
.

When is IN8bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our INAB earnings forecast
.

How were IN8bio's earnings last quarter?

IN8bio, Inc. (NASDAQ:INAB) released its earnings results on Thursday, March, 14th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.05.

When did IN8bio IPO?

IN8bio (INAB) raised $44 million in an IPO on Friday, July 30th 2021. The company issued 4,000,000 shares at $10.00-$12.00 per share. B. Riley Securities served as the underwriter for the IPO.

How do I buy shares of IN8bio?

Shares of INAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:INAB) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners